Buller RE - Search Results

1

Ovarian cancer p53 mutation is associated with tumor microvessel density.

Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE. Goodheart MJ, et al. Among authors: buller re. Gynecol Oncol. 2002 Jul;86(1):85-90. doi: 10.1006/gyno.2002.6730. Gynecol Oncol. 2002. PMID: 12079305

2

p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma.

Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz A. Sood AK, et al. Among authors: buller re. Cancer Biol Ther. 2002 Sep-Oct;1(5):511-7. doi: 10.4161/cbt.1.5.167. Cancer Biol Ther. 2002. PMID: 12496479 Free article.

3

p21 expression predicts outcome in p53-null ovarian carcinoma.

Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Buller RE. Rose SL, et al. Among authors: buller re. Clin Cancer Res. 2003 Mar;9(3):1028-32. Clin Cancer Res. 2003. PMID: 12631602

4

The influence of microvessel density on ovarian carcinogenesis.

Stone PJ, Goodheart MJ, Rose SL, Smith BJ, DeYoung BR, Buller RE. Stone PJ, et al. Among authors: buller re. Gynecol Oncol. 2003 Sep;90(3):566-71. doi: 10.1016/s0090-8258(03)00367-6. Gynecol Oncol. 2003. PMID: 13678725

5

The impact of p53 protein core domain structural alteration on ovarian cancer survival.

Rose SL, Robertson AD, Goodheart MJ, Smith BJ, DeYoung BR, Buller RE. Rose SL, et al. Among authors: buller re. Clin Cancer Res. 2003 Sep 15;9(11):4139-44. Clin Cancer Res. 2003. PMID: 14519637

6

The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.

Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, Buller RE. Goodheart MJ, et al. Among authors: buller re. Clin Cancer Res. 2005 May 15;11(10):3733-42. doi: 10.1158/1078-0432.CCR-04-0056. Clin Cancer Res. 2005. PMID: 15897570

7

Ovarian cancer genomic instability correlates with p53 frameshift mutations.

Sood AK, Skilling JS, Buller RE. Sood AK, et al. Among authors: buller re. Cancer Res. 1997 Mar 15;57(6):1047-9. Cancer Res. 1997. PMID: 9067268

8

Drug resistance in ovarian cancer: from the laboratory to the clinic.

Sood AK, Buller RE. Sood AK, et al. Among authors: buller re. Obstet Gynecol. 1998 Aug;92(2):312-9. doi: 10.1016/s0029-7844(98)00184-7. Obstet Gynecol. 1998. PMID: 9699774 Review.

9

Distant metastases in ovarian cancer: association with p53 mutations.

Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE. Sood AK, et al. Among authors: buller re. Clin Cancer Res. 1999 Sep;5(9):2485-90. Clin Cancer Res. 1999. PMID: 10499623

10

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.

Shahin MS, Hughes JH, Sood AK, Buller RE. Shahin MS, et al. Among authors: buller re. Cancer. 2000 Nov 1;89(9):2006-17. doi: 10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.3.co;2-z. Cancer. 2000. PMID: 11064359

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

131 results

Search Page

Filters